scholarly journals Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

2022 ◽  
Author(s):  
Ronald Wit ◽  
Thomas Powles ◽  
Daniel Castellano ◽  
Andrea Necchi ◽  
Jae‐Lyun Lee ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Iii ◽  
Response Relationship ◽  
Phase Iii Trial ◽  
Exposure Response ◽  
Advanced Urothelial Carcinoma ◽  
Relationship Of

scholarly journals Exposure Response Relationship of Acute Effects of Air Pollution on Respiratory Diseases — China, 2013−2018

2021 ◽  
Vol 3 (45) ◽  
pp. 943-947
Author(s):  
Hongtao Niu ◽  
◽  
Tao Yu ◽  
Xuexin Li ◽  
Hanna Wu ◽  
...  
Keyword(s):  
Air Pollution ◽  
Respiratory Diseases ◽  
Response Relationship ◽  
Acute Effects ◽  
Exposure Response ◽  
Relationship Of

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

1997 ◽  
Vol 15 (7) ◽  
pp. 2564-2569 ◽  
Author(s):  
S B Saxman ◽  
K J Propert ◽  
L H Einhorn ◽  
E D Crawford ◽  
I Tannock ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Combination Chemotherapy ◽  
Performance Status ◽  
Single Agent ◽  
Phase Iii ◽  
Long Term Follow Up ◽  
Intergroup Trial ◽  
Advanced Urothelial Carcinoma

PURPOSE A previously reported randomized intergroup trial demonstrated that combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) was superior to single-agent cisplatin in patients with advanced urothelial carcinoma. We conducted a long-term analysis of patients included in the intergroup trial to examine factors associated with long-term survival. PATIENTS AND METHODS Two-hundred fifty-five assessable patients with urothelial carcinoma were randomized to receive either single-agent cisplatin (70 mg/m2 on day 1) or combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2). Courses were repeated every 28 days. The association between patient characteristics and survival was assessed using Cox proportional hazards models. RESULTS With long-term follow-up evaluation, survival in the M-VAC arm continues to be superior to cisplatin (P = .00015, log-rank test). Predictors of survival include performance status, histology, and the presence of liver or bone metastasis. Only 3.7% of the patients randomized to M-VAC are alive and continuously disease-free at 6 years. CONCLUSION Long-term follow-up evaluation of the intergroup trial confirms that M-VAC is superior to single-agent cisplatin in patients with advanced urothelial carcinoma; however, durable progression-free survival is rare. Patients with non-transitional-cell histology, poor performance status, and/or bone or visceral involvement fare poorly and are unlikely to benefit significantly from M-VAC chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document